Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on May 26, 2009
JNCI Journal of the National Cancer Institute 2009 101(11):780-781; doi:10.1093/jnci/djp150
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
101/11/780    most recent
djp150v3
djp150v2
djp150v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Brower, V.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brower, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2009.

NEWS

Antiangiogenesis Research Is Booming, As Questions and Studies Proliferate

Vicki Brower

The first 10% of the full text of this article appears below.

In a recent analysis of a large observational study, bevacizumab (Avastin), an inhibitor of angiogenesis, was associated with favorable survival rates in patients whose colorectal cancer had already progressed. Those taking bevacizumab with chemotherapy had a median overall survival of 32 months, compared with 20 months for those who did not receive bevacizumab beyond first-line therapy. The difference was statistically significant.

The analysis, published in November, was based on data from a patient registry known as BRiTE, which is designed primarily to gather information on adverse events and secondarily on progression-free and overall survival. Nevertheless, the positive results buoyed researchers.

"We did not expect patients to receive such a magnitude of benefit," said lead investigator Axel Grothey, M.D., a professor at the Mayo Clinic in Rochester, Minn. The researchers concluded that bevacizumab beyond initial disease progression might benefit patients who . . . [Full Text of this Article]

Treatment After Progression?

Measuring AI Effects

How They Work

Rebound Effect


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?